Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients

Trial Profile

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Prednisone
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Visual I
  • Sponsors Abbott Healthcare; AbbVie
  • Most Recent Events

    • 01 Dec 2017 Results of a post-hoc analysis from VISUAL-1 and VISUAL-2 studies assessing the association between corticosteroid dosage and incidence rates of corticosteroid-related adverse events, published in the Ophthalmology.
    • 17 Jun 2017 Results of exploratory analysis of VISUAL I and VISUAL II trials presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 28 Sep 2016 According to an AbbVie and Eisai media release, based on the results of VISUAL-I and VISUAL-II, and VISUAL-III , adalimumab was granted additional approval in Japan, for the treatment of non-infectious intermediate, posterior and panuveitis, regardless of underlying disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top